Assignee
SHANDONG XUANZHU PHARMA CO LTD
CN·2 granted patents·4 pending applications·0 citations·filing 2020–2023
Top patents by PatentIndex Score
6 records- 0160US2024101566A1Tricyclic ubiquitin specific protease 1 inhibitor and use thereofSHANDONG XUANZHU PHARMA CO LTD·Filed 2023·Application pending·0 cites
- 0251US12441717B2Crystal form of polycyclic anaplastic lymphoma kinase inhibitorSHANDONG XUANZHU PHARMA CO LTD·Filed 2021·Granted Oct 14, 2025·0 cites·20 claims
- 0351US2024083917A1Polycyclic Kinase InhibitorSHANDONG XUANZHU PHARMA CO LTD·Filed 2022·Application pending·0 cites
- 0451US2023183265A1Crystal Form of Macrocyclic Tyrosine Kinase Inhibitor and Preparation Method thereforSHANDONG XUANZHU PHARMA CO LTD·Filed 2021·Application pending·0 cites
- 0550US2023271947A1Salt and crystal form of ketohexokinase inhibitor and use thereofSHANDONG XUANZHU PHARMA CO LTD·Filed 2023·Application pending·0 cites
- 0646US12331038B2Hexone glucokinase inhibitor and use thereofSHANDONG XUANZHU PHARMA CO LTD·Filed 2020·Granted Jun 17, 2025·0 cites·9 claims
Join the waitlist — get patent alerts
Get an alert when SHANDONG XUANZHU PHARMA CO LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →